RecruitingPhase 2NCT05648019

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
KK Women's and Children's Hospital
Principal Investigator
Shui Yen Soh, MD
KK Women's and Children's Hospital
Intervention
Anti-CD19 CAR T-cells(biological)
Enrollment
40 enrolled
Eligibility
0-70 years · All sexes
Timeline
20222026

Study locations (2)

Collaborators

Singapore General Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05648019 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials